155412-18-3

Basic information

• Product Name: Ethanone, 2-bromo-1-cycloheptyl- (9CI)
• Synonyms: Ethanone, 2-bromo-1-cycloheptyl- (9CI);2-Bromo-1-cycloheptylethanone
• CAS NO: 155412-18-3
• Molecular Formula: C₉H₁₅BrO
• Molecular Weight: 219.1188
• Product Categories: ACETYLHALIDE
• Mol File: 155412-18-3.mol

Chemical Properties

• Boiling Point: 272.4±13.0 °C(Predicted)
• Appearance: /
• Density: 1.299±0.06 g/cm3(Predicted)
• CAS DataBase Reference: Ethanone, 2-bromo-1-cycloheptyl- (9CI)(CAS DataBase Reference)
• NIST Chemistry Reference: Ethanone, 2-bromo-1-cycloheptyl- (9CI)(155412-18-3)
• EPA Substance Registry System: Ethanone, 2-bromo-1-cycloheptyl- (9CI)(155412-18-3)

Safety Data

• Hazardous Substances Data: 155412-18-3(Hazardous Substances Data)

Upstream product

• 1460-16-8 cycloheptanoic acid 
• 18107-18-1 diazomethyl-trimethyl-silane 
• 6713-48-0 1-cycloheptylethan-1-one 

Downstream Products

• 156589-72-9 (E)-4-cycloheptyl-2-[2-(3-nitrophenyl)ethenyl]thiazole 

Relevant articles and documents

Heteroaryl 11-beta-hydroxysteroid dehydrogenase type I inhibitors

Novel compounds are provided which are 11-beta-hydroxysteroid dehydrogenase type I inhibitors. 11-beta-hydroxysteroid dehydrogenase type I inhibitors are useful in treating, preventing, or slowing the progression of diseases requiring 11-beta-hydroxystero

THERAPEUTIC AGENT FOR DIABETES

A therapeutic agent for diabetes, which comprises a compound of the formula [I] wherein Xis a group of the formula wherein R4and R5are the same or different and each is a hydrogen atom, an optionally substituted alkyl having 1 to 5 carbon atoms and the like, and R6is a hydrogen atom or an amino-protecting group; R1is an optionally substituted alkyl having 1 to 5 carbon atoms, an optionally substituted alkenyl having 2 to 6 carbon atoms and the like, R2is a hydrogen atom, an optionally substituted alkyl having 1 to 5 carbon atoms and the like, R2' is a hydrogen atom, and R3is an optionally substituted alkyl having 1 to 5 carbon atoms and the like, a prodrug thereof, a pharmaceutically acceptable salt thereof, a hydrate thereof and a solvate thereof. The compound of the present invention shows superior blood sugar decreasing action on the state of hyperglycemia, but does not affect the blood sugar when it is in the normal range or in the hypoglycemic state, which means that it is free of serious side effects such as hypoglycemia. Therefore, the compound of the present invention is useful as a therapeutic drug for diabetes and also useful as a preventive of the chronic complications of diabetes.

CYCLOALKYLTHILAZOLES

Compounds of the formula: STR1 wherein the substituents are as described in the specification, antagonize LTD 4 action and thus, are useful in treating bronchial asthma, pulmonary anaphylaxis, cystic fibrosis, chronic bronchitis, bronchiectasis, respiratory distress syndrome and pulmonary oedema.